{"id":"NCT00515619","sponsor":"UCB Pharma","briefTitle":"Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures","officialTitle":"An International Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral Lacosamide (SPM 927) in Patients With Partial Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-12","primaryCompletion":"2010-08","completion":"2010-08","firstPosted":"2007-08-14","resultsPosted":"2011-09-09","lastUpdate":"2017-08-28"},"enrollment":376,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Lacosamide","otherNames":["SPM 927","LCM"]}],"arms":[{"label":"Lacosamide","type":"EXPERIMENTAL"}],"summary":"The main purpose of this trial is to determine safety and efficacy of Lacosamide under long term therapy.","primaryOutcome":{"measure":"Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) During the Treatment Period (up to 5.5 Years)","timeFrame":"During the Treatment Period (up to 5.5 years)","effectByArm":[{"arm":"Lacosamide","deltaMin":311,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":54,"countries":["Australia","Croatia","Czechia","Finland","France","Germany","Hungary","Lithuania","Poland","Russia","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["24275520","26133811"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":87,"n":376},"commonTop":["Dizziness","Headache","Nasopharyngitis","Diplopia","Vertigo"]}}